This statistic compares brand drug prescription revenues of branded and unbranded generics in the United States from 2005 to 2015. In 2005, some 81 percent of total U.S. prescription revenues were made through brand name medications. However, this share decreased to some 71 percent in 2013, and increased slightly to over 74 percent in 2016. Generics are copies or equivalents of once patent protected drugs, containing the same active ingredient, in the same amount, in the same form, dissolving at the same rate in equal amounts like the original.
- Health & Pharmaceuticals›
- Pharmaceutical Products & Market›
U.S. brand and generic prescription drug revenue 2005-2016
Premium statistics
Industry-specific and extensively researched technical data (partially from exclusive partnerships).
A paid subscription is required for full access.
Proportion of branded versus generic prescription drug revenues in the United States from 2005 to 2016
Exclusive Premium Statistic
This statistic compares brand drug prescription revenues of branded and unbranded generics in the United States from 2005 to 2015. In 2005, some 81 percent of total U.S. prescription revenues were made through brand name medications. However, this share decreased to some 71 percent in 2013, and increased slightly to over 74 percent in 2016. Generics are copies or equivalents of once patent protected drugs, containing the same active ingredient, in the same amount, in the same form, dissolving at the same rate in equal amounts like the original.
| Brands | Branded Generics | Unbranded Generics | |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Brands | Branded Generics | Unbranded Generics | |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
Exclusive content
Exclusive Premium statistic
Get a Premium Account for unrestrained access.
Benefits of our Premium membership:
- Access to all Premium statistics
- Download as XLS, PNG and PDF
- Detailed source and background information
Premium Account
$49 per month*
(billed annually)
(billed annually)
Exclusive content
Exclusive Premium statistic
Get a Premium Account for unrestrained access.
Benefits of our Premium membership:
- Access to all Premium statistics
- Download as XLS, PNG and PDF
- Detailed source and background information
Premium Account
$49 per month*
(billed annually)
(billed annually)
About this statistic
Show source
Download
Settings
Share
Chart type
Datalabels
Share on Social Media
Download started
Please be patient - this may take a moment
Please be patient - this may take a moment
Description
Source
More information
This statistic compares brand drug prescription revenues of branded and unbranded generics in the United States from 2005 to 2015. In 2005, some 81 percent of total U.S. prescription revenues were made through brand name medications. However, this share decreased to some 71 percent in 2013, and increased slightly to over 74 percent in 2016. Generics are copies or equivalents of once patent protected drugs, containing the same active ingredient, in the same amount, in the same form, dissolving at the same rate in equal amounts like the original.
Show more- Show sources information
- Show publisher information
- Release date
- May 2017
- Region
- United States
- Survey time period
- 2005 to 2016
- Supplementary notes
-
Report reflects prescription-bound products including insulins and excluding other products such as OTC.
Includes prescriptions and insulins dispensed by chain and independent pharmacies, food store pharmacies, mail service pharmacies, and long-term
care facilities. Spending figures also include sales into hospitals, clinics, and other institutional settings.
Prescription counts are not adjusted for length of therapy. 90-day and 30-day prescriptions are both counted as one prescription.
This statistic was assembled from several IMS Health/QuintilesIMS reports.
More information
- Region
- United States
- Survey time period
- 2005 to 2016
- Supplementary notes
-
Report reflects prescription-bound products including insulins and excluding other products such as OTC.
Includes prescriptions and insulins dispensed by chain and independent pharmacies, food store pharmacies, mail service pharmacies, and long-term
care facilities. Spending figures also include sales into hospitals, clinics, and other institutional settings.
Prescription counts are not adjusted for length of therapy. 90-day and 30-day prescriptions are both counted as one prescription.
This statistic was assembled from several IMS Health/QuintilesIMS reports.
Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account!
Premium Account
Your perfect start with Statista
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$49 / Month *
Corporate Account
Full access
Corporate solution including all features.
* All products require an annual contract.
Prices do not include sales tax
(New York residents only).
Prices do not include sales tax
(New York residents only).
Leading companies trust Statista:
Related Studies: Available to Download in PDF or PPTX Format
All Information
in one Presentation
Generics and biosimilars
- 86 page/s
- English
- pptx
- Detailed references
Everything On "Generics and biosimilars" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.
Other Reports & Dossiers
I think of Statista as Google for researchers. Statista provides you with the information you search for right away.Dr. Horst Stipp
EVP, Research & Innovation, Advertising Research Foundation
Statistics on "Generics and biosimilars"
- Global overview
The most important statistics
- Global pharmaceutical market revenue from 2008 to 2015 (in billion U.S. dollars)*Global pharmaceutical market revenue 2008-2015
- Worldwide total generic prescription drug revenue from 2010 to 2024 (in billion U.S. dollars)Total worldwide generic prescription drug revenue 2010-2024
- Worldwide generic prescription drug revenue as a percent of total prescribed revenue from 2010 to 2024Global generic prescription drug revenues as share of prescribed revenue 2010-2024
- Worldwide total prescription drug revenue at risk from patent expiration from 2010 to 2024 (in billion U.S. dollars)*Patent expiration risks for total worldwide prescription drug revenue 2010-2024
- Top companies
The most important statistics
- Top 20 generic pharmaceutical companies worldwide in 2015, by revenue (in million U.S. dollars)Top global generic pharmaceutical companies 2015, by revenue
- Top 20 generic pharmaceutical companies worldwide as of 2016, by enterprise value (in million U.S. dollars)Top global generic pharmaceutical companies, by enterprise value 2016
- Value share of top 10 generic pharmaceutical companies worldwide as of 2016*Top global generic pharmaceutical company value share 2016
- Generic revenues of Teva Pharmaceutical Industries from 2014 to 2017, by region (in million U.S. dollars)Teva Pharmaceutical Industries' generic revenues by region 2014-2017
- Pfizer's revenue in 2014 and 2017, by segment (in million U.S. dollars)*Pfizer's revenue by segment 2014-2017
- Top 10 generic drug manufacturers worldwide based on market share in 2014*Leading global generic drug manufacturers by market share 2014
- U.S. market
The most important statistics
- Brand and generic prescription medication revenue in the U.S. from 2006 to 2016 (in billion U.S. dollars)*Brand and generic prescription medication revenue in the U.S. 2006-2016
- Proportion of branded versus generic prescription drug revenues in the United States from 2005 to 2016U.S. brand and generic prescription drug revenue 2005-2016
- Change in branded and generic medication spending in the United States from 2009 to 2015 (in billion U.S. dollars)Spending change on branded and generic medicines in the U.S. 2009-2015
- Top 20 generic pharmaceutical companies with a U.S. operating presence as of 2016, by enterprise value (in million U.S. dollars)Enterprise value of generic pharmaceutical companies with a U.S. presence 2016
- Top 20 generic pharmaceutical companies with a U.S. operating presence in 2015, by revenue (in million U.S. dollars)Revenue of top generic pharma companies with U.S. presence 2015
- Top 20 U.S. pharma products by dispensed prescriptions in 2016 (in millions)Top U.S. pharma products by prescriptions 2016
- Top U.S. generic pharmaceutical industry acquisitions in 2015 (in billion U.S. dollars)U.S. generic pharmaceutical industry top acquisitions 2015
- Patent expiration
The most important statistics
- Major generic introductions of branded drugs in the U.S. in 2016, by sales (in million US dollars)*Estimated sales of major generic introductions in U.S. 2016
- Leading drugs going off patent in the U.S. in 2017, by revenue (in million U.S. dollars)*Biggest selling drugs with patent at threat in the U.S. in 2017, by revenue
- Share of company sales of leading drugs going off patent in the U.S. in 2017*Share of company sales of biggest selling drugs going generic in the U.S. in 2017
- Reduction in value due to expiring patents in the United States from 2016 to 2019 (in billion U.S. dollars)*Value of expiring patents in U.S. 2016-2019
- Comparison of brand pre-expiry price and generic price of selected drugs in the United States as of 2015 (in U.S. dollars)Comparison of pre-expiry and generic price for drugs U.S. 2015
- Monthly price reduction of generic drugs after loss of exclusivity in the United States as of 2015Price reduction of generic drugs after loss of exclusivity in the U.S. 2015
- Savings
The most important statistics
- Savings through generic drug usage in the United States from 2008 to 2017 (in billion U.S. dollars)Savings through generic drug usage in the U.S. 2008-2017
- Cost savings through generics in the United States in 2017, by therapeutic area (in billion U.S. dollars)*Saving of U.S. costs through generic pharmaceuticals by therapy 2017
- Savings through generic drug usage in the United States in 2017, by age group (in billion U.S. dollars)Savings through generic drug usage in the U.S., by age group 2017
- Savings through generic drug usage in the United States in 2017, by payer (in billion U.S. dollars)Savings through generic drug usage in the U.S., by payer 2017
- Savings through generic drug usage in Medicaid during 2015, by state (in million U.S. dollars)Medicaid program savings through generic drug usage by U.S. state 2015
- Savings through generic drug usage in Medicare during 2015, by state (in million U.S. dollars)*Medicare savings through generic drug usage in the U.S. by state 2015
- Top generic drugs based on savings in the United States in 2017 (in million U.S. dollars)Total savings of top generic drugs in U.S. 2017
- Biosimilars
The most important statistics
- Major biologics scheduled to lose patent protection between 2015 and 2020, by combined EU-5 and U.S. revenue (in billion euros)*Major biologics to lose patent protection 2015-2020 by EU5 and U.S. revenue
- Cumulative potential biosimilars market in EU-5 countries and the U.S. between 2016 and 2020 (in billion euros)Cumulative potential biosimilars market in EU5 countries and the U.S. 2016-2020
- Potential savings due to biosimilars for 8 key products combined in EU-5 countries and the U.S. between 2016 and 2020 (in billion euros)*Potential biosimilars savings in EU5 countries and the U.S. 2016-2020
- Global market forecast for oncologics and supportive care biosimilars in 2015 and 2020 (in billion U.S. dollars)Global market forecast of oncologics and supportive care biosimilars 2020
- Percentage of U.S. health care executives who foresee biosimilars reducing drug spend for specialty drugs in 2017-2020*Opinion on drug spending reduction due to biosimilars for specialty drugs 2017-2020
- Example of physician office payment for biosimilars in Medicare Part B as of 2018 (in U.S. dollars)*Physician office payment for biosimilars in Medicare Part B in 2018
- Planned initiatives of managed care organizations (MCOs) after first biosimilar is marketed in the United States as of 2015First biosimilar marketing initiatives by MCOs in U.S. 2015
- Knowledge about biosimilars among consumers in the United States as of 2015U.S. consumers knowledge about biosimilars 2015
Popular Related Keywords
- brands
- drug
- revenue distribution
- generic drug
- sales
- Show more
- prescription
- drugs
- health
- health service
- branded products
- Pharmaceutical companies
- consumer health care
- healthcare
- generics
- consumer health products
- pharmaceutical products
- pharmaceutical regulations
- brand popularity
- pharmaceutical industry
- generics market
- generics manufacturers
- health sector
- pharmaceutical manufacturers
- retail brand share
- pharmaceutical data
- health market
- pharmaceutical business
- pharmaceutical market
- drug prescription rates
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Statistics
- Dispensing costs for tablets of generic drugs by public drug plan 2015/16
- Top generics producing companies by prescriptions dispensed 2010
- U.S. spending on biosimilars by type 2014
- U.S. spending on multiple sclerosis medicine by type 2010-2014
- U.S. spending growth on new brand specialty medicine by type 2014-2015
- U.S. spending on specialty medicine by type 2012-2016
- Spending on dispensed total vs. generic prescriptions in the U.S. 2017
- Number of ANDA approvals in U.S. 2015-2017, by type
- Generic share of dispensed prescriptions by formulation U.S. 2012 vs. 2017
- U.S. total vs. generic dispensed prescription numbers 2017, by formulation
- Percentage savings through generic drug usage in the U.S. by payer 2017
- Average number of approved ANDAs per month in U.S. 2009-2017
- Number of approved ANDAs in U.S. 2009-2017
- Average number of ANDAs received per month in U.S. 2009-2017
- Generics prescriptions dispensed in the U.S. 2010-2016
- Volume share of generic pharmaceuticals in Finland 2007-2015
- Italy: sales volume share of generic drugs 2017, by region
- Drug shortages of individual drugs experienced by hospitals in U.S.
- Drug cost distribution by drug type in public drug plans Canada 2015/2016
- Generic drugs revenue in prescribed drug market in India 2008-2015
Studies
- Prescribed Drug Spending in Canada, 2017
- CDER 2017 New Drug Therapy Approvals
- Drug Use Among Seniors in Canada, 2016
- Compass Rx - Annual Public Drug Plan Expenditure Report 2015/16
- Prescribed Drug Spending in Canada, 2016
- CDER New Drug Review: 2016 Update
- Meds Entry Watch 2016
- CDER New Drugs Program: 2017 Update
- Compass Rx - Annual Public Drug Plan Expenditure Report 2012/13
- Showdown over drug pricing
- Patented Medicine Prices Review Board - Annual Report 2017
- Trends in Retail Prices of Prescription Drugs Widely Used by Older Americans: 2006 to 2015
- Prescribed Drug Spending in Canada, 2013
- Compass Rx - Annual Public Drug Plan Expenditure Report 2013/14
- Top 200 Products in the US Market by Sales, 2009
Statistics on the topic
Free statistics
- Top 20 generic pharmaceutical companies worldwide in 2015, by revenue (in million U.S. dollars)
- Value share of top 10 generic pharmaceutical companies worldwide as of 2016*
- Top 10 generic drug manufacturers worldwide based on market share in 2014*
- Change in branded and generic medication spending in the United States from 2009 to 2015 (in billion U.S. dollars)
- Reduction in value due to expiring patents in the United States from 2016 to 2019 (in billion U.S. dollars)*
- Comparison of brand pre-expiry price and generic price of selected drugs in the United States as of 2015 (in U.S. dollars)
- Monthly price reduction of generic drugs after loss of exclusivity in the United States as of 2015
- Potential savings due to biosimilars for 8 key products combined in EU-5 countries and the U.S. between 2016 and 2020 (in billion euros)*
- Percentage of U.S. health care executives who foresee biosimilars reducing drug spend for specialty drugs in 2017-2020*
- Example of physician office payment for biosimilars in Medicare Part B as of 2018 (in U.S. dollars)*
- Planned initiatives of managed care organizations (MCOs) after first biosimilar is marketed in the United States as of 2015
- Knowledge about biosimilars among consumers in the United States as of 2015
- Dispensing costs for tablets of common generic drugs by public drug plan in Canada comparing FY 2011/12 and FY 2015/16 (in 1,000 Canadian dollars)*
- Spending growth on new brand specialty medicines in the United States in 2014 and 2015, by type (in billion U.S. dollars)
- Spending on dispensed total vs. generics prescriptions in the U.S. in 2017, by formulation (in billion U.S. dollars)
- Number of abbreviated new drug applications (ANDAs) approvals in the U.S. from 2015 to 2017, by type of approval
- Number of dispensed total vs. generics prescriptions in the U.S. in 2017, by formulation (in millions)
- Percentage of savings through generic drug usage in the United States in 2017, by payer
- Total number of generic drug prescriptions dispensed in the U.S. from 2010 to 2016 (in millions)*
- Distribution of drug costs by drug type in select public Canadian drug plans as of FY 2015/2016
Premium Statistics
- Global pharmaceutical market revenue from 2008 to 2015 (in billion U.S. dollars)*
- Worldwide total generic prescription drug revenue from 2010 to 2024 (in billion U.S. dollars)
- Worldwide generic prescription drug revenue as a percent of total prescribed revenue from 2010 to 2024
- Worldwide total prescription drug revenue at risk from patent expiration from 2010 to 2024 (in billion U.S. dollars)*
- Top 20 generic pharmaceutical companies worldwide as of 2016, by enterprise value (in million U.S. dollars)
- Generic revenues of Teva Pharmaceutical Industries from 2014 to 2017, by region (in million U.S. dollars)
- Pfizer's revenue in 2014 and 2017, by segment (in million U.S. dollars)*
- Brand and generic prescription medication revenue in the U.S. from 2006 to 2016 (in billion U.S. dollars)*
- Proportion of branded versus generic prescription drug revenues in the United States from 2005 to 2016
- Top 20 generic pharmaceutical companies with a U.S. operating presence as of 2016, by enterprise value (in million U.S. dollars)
- Top 20 generic pharmaceutical companies with a U.S. operating presence in 2015, by revenue (in million U.S. dollars)
- Top 20 U.S. pharma products by dispensed prescriptions in 2016 (in millions)
- Top U.S. generic pharmaceutical industry acquisitions in 2015 (in billion U.S. dollars)
- Major generic introductions of branded drugs in the U.S. in 2016, by sales (in million US dollars)*
- Leading drugs going off patent in the U.S. in 2017, by revenue (in million U.S. dollars)*
- Share of company sales of leading drugs going off patent in the U.S. in 2017*
- Savings through generic drug usage in the United States from 2008 to 2017 (in billion U.S. dollars)
- Cost savings through generics in the United States in 2017, by therapeutic area (in billion U.S. dollars)*
- Savings through generic drug usage in the United States in 2017, by age group (in billion U.S. dollars)
- Savings through generic drug usage in the United States in 2017, by payer (in billion U.S. dollars)
- Savings through generic drug usage in Medicaid during 2015, by state (in million U.S. dollars)
- Savings through generic drug usage in Medicare during 2015, by state (in million U.S. dollars)*
- Top generic drugs based on savings in the United States in 2017 (in million U.S. dollars)
- Major biologics scheduled to lose patent protection between 2015 and 2020, by combined EU-5 and U.S. revenue (in billion euros)*
- Cumulative potential biosimilars market in EU-5 countries and the U.S. between 2016 and 2020 (in billion euros)
- Global market forecast for oncologics and supportive care biosimilars in 2015 and 2020 (in billion U.S. dollars)
- Top 10 generic drugs producing pharmaceutical companies by U.S. prescriptions dispensed in 2010 (in millions)*
- Expenditure on biosimilars in the United States in 2014, by type (in billion U.S. dollars)*
- Expenditure on multiple sclerosis medicines in the United States from 2010 to 2014, by type (in billion U.S. dollars)
- Expenditure on specialty medicines in the United States from 2012 to 2016, by type (in billion U.S. dollars)
- Percentage of U.S. dispensed prescriptions that were generics in 2012 and 2017, by formulation
- Average number of approved abbreviated new drug applications (ANDAs) per month in the U.S. from 2009 to 2017
- Number of approved abbreviated new drug applications (ANDAs) in the U.S. from 2009 to 2017
- Average number of abbreviated new drug applications (ANDAs) received per month in the U.S. from 2009 to 2017
- Share of generic pharmaceuticals market volume in Finland from 2007 to 2015
- Sales volume share of generic drugs* in Italy in 2017, by region
- Percent of hospitals experiencing a drug shortage in the last six months by treatment category
- Revenue of generic drugs in the prescribed drug market in India from 2008 to 2015 ( in billion U.S. dollars)
Statista Accounts: Access All Statistics. Starting from $588 / Year
Topics
About Statista
Statista offers dossiers and reports on over 170 industries. With Statista you are always able to make informed decisions and boost your work efficiency.
Internet & Telecommunications
- Social Media
- E-Commerce
- Online Video & Entertainment
- Advertising & Marketing
Consumer Goods & FMCG
- Alcoholic Beverages
- Cleaning Products
- Cosmetics & Personal Care
- Food & Nutrition
Retail & Trade
- Health & Hygiene
- International Trade
- Shopping Behavior
- Sports & Leisure
Travel, Tourism & Hospitality
- Business Travel
- Leisure Travel
- Accomodation
- Restaurants
Society
- Demographics
- Economy
- Education & Science
- Politics & Government
Transportation & Logistics
- Aviation
- Rail Transport
- Vehicles & Road Traffic
- Water Transport
Exclusive Premium functionality
Register in seconds and access exclusive features.
- Full access:
To this and over 1 million additional datasets - Save Time:
Downloads allow integration with your project - Valid data:
Access to all sources and background information
Exclusive Corporate feature
This feature is limited to our corporate solutions.
Please contact us to get started with full access to dossiers, forecasts, studies and international data.
Corporate Account
News
Latest News
New
New Topic Page: Trade across the Irish border
With the UK making plans to leave the EU, it is still uncertain about how this will affect trade across the UK's only land border, the Irish border. This topic highlights the importance of cross border trade and discusses how firms across Ireland are anticipating Brexit to impact their businesses.
New
Global Industry Reports available now!
Statista now offers industry insights from a global perspective for 34 industries. The reports provide crucial information on the trends moving all major industries. Get a bird’s-eye view on your industry, complete with all essential data, KPIs, and exclusive Statista data.
New
New Smart TV Industry Whitepaper
Statista Research and Analysis, in cooperation with Chinese smart TV manufacturer TCL Multimedia and its subsidiary FFalcon Technology, is going to present a new white paper on the global Smart TV industry on September 15th, 2018 during the International Broadcasting Convention (IBC) in Amsterdam.
New
New Dossier: Electric vehicles in Italy
Is Italy speeding up on electric mobility or is the next charging point still too far away? Have a deeper look into the topic with this new dossier. Statista provides an overview on the market situation and customer attitudes around e-mobility in this country so passionate about cars.
New
New Topic Page: Brexit negotiations
With an October deadline looming and an unpopular proposal in hand, time is running out for Theresa May to secure a deal with the European Union. This topic highlights some the main issues standing in the way of a deal and explores how the British public have reacted to the ongoing political drama.
New
New Dossier: eSports in the Benelux region
Revenue might still pale in comparison to other sports, but the recent growth of electronic sports, or eSports, has been immense. This dossier analyzes the popularity of video games and digital games in the Netherlands and the attitude shown towards the trend of online gaming.
New
New topic page: Organic cosmetics in the UK
As consumers become aware of the potentially harmful ingredients used in conventional beauty products, many are seeking green alternatives which pose a lesser risk to the skin and the environment. This topic page provides an overview of natural and organic cosmetic sales and UK consumer attitudes.
New
New Statista Study: European Football Benchmark
Just in time for the start of the new Premier League season, Statista launches the European Football Benchmark: The first football study that compares the 5 big European leagues from a fan's perspective. Find out everything about the Premier League, its clubs, sponsors and fans.
New
New tutorial video on the Global Consumer Survey
The Statista Global Consumer Survey offers a global perspective on consumption and media usage, covering the offline and online world of the consumer. The new tutorial video shows all functionalities and illustrates how you can use the DIY analysis tool effectively.
New
Consumer Electronics Report 2018 out now!
Market reports for the Statista Consumer Market Outlook will now be released roughly every other week starting with the Consumer Electronics Report 2018. The market reports include data as well as qualitative insights into market drivers, consumer behaviour, trends, sales channels and key players.
Updated
In-depth eMobility Report updated & extended
The trend topic eMobility affects many industries and constantly attracts new players. Our updated in-depth report contains all relevant data and insights and includes an excel file with a detailed list of electric cars, trucks, cargo vehicles, buses, and their specifications.
New
New Market: Luxury Goods
The Consumer Market Outlook now includes historical market sizes and forecasts for 9 personal luxury goods categories as well as company data on key players in 50 countries.
We use cookies to personalize contents and ads, offer social media features, and analyze access to our website. In your browser settings you can configure or disable this, respectively, and can delete any already placed cookies. For details, please see your browser’s Help section (by pressing F1). Please see our privacy statement for details about how we use data.